United States Biotechnology & Medical Research

Enliven Therapeutics Inc (ELVN)

Track

Enliven Therapeutics Inc. has seen significant insider selling over the past 90 days, with 47 transactions totaling approximately $152.6 million in sales. Major shareholders, including OrbiMed entities, account for the bulk of this activity. These sales occur as the stock trades near its 52-week high following a positive earnings report in May.

Active selling signal · Moderate

Top insider sells (90, 60d)

Featured in screeners

Active selling signal · Moderate

Top insider sells

Ticker: ELVN Exchange: NSM

• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings

Insider activity signal detected

13 activity signals detected for Enliven Therapeutics Inc

Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Enliven Therapeutics Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →

Top insiders

Company data & Insiders

Subscribe to get access to the company description and key fundamental data (market cap, shares outstanding, dividend yield, % of shares held by insiders and more)

Download results Settings

Trades

Hohl Benjamin

CHIEF FINANCIAL OFFICER

5 sales — total 500,000 USD

Planned sale 17 Jul 2026

Value US$621,546.44 | Price 234.18 | Shares 29,127

Planned sale 17 Jul 2026

Value US$1,898,350.17 | Price 357.85 | Shares 40,060

Planned sale 17 Jul 2026

Value US$100,000.00 | Price 52.32 | Shares 1,000

Planned sale 17 Jul 2026

Value US$100,000.00 | Price 51.48 | Shares 1,000

Planned sale 17 Jul 2026

Value US$100,000.00 | Price 49.97 | Shares 1,000

Collins Helen Louise

CHIEF MEDICAL OFFICER

6 sales — total 600,000 USD

Planned sale 17 Jul 2026

Value US$4,583,490.91 | Price 350.38 | Shares 36,335

Planned sale 17 Jul 2026

Value US$3,431,778.65 | Price 18.38 | Shares 35,361

Planned sale 17 Jul 2026

Value US$100,000.00 | Price 52.39 | Shares 1,000

Planned sale 17 Jul 2026

Value US$100,000.00 | Price 51.55 | Shares 1,000

Planned sale 17 Jul 2026

Value US$100,000.00 | Price 50.05 | Shares 1,000

Proposed sale 17 Jul 2026

Value US$100,000.00 | Price 50.86 | Shares 1,000

Kunkel Lori Anne

2 sales — total 200,000 USD

Planned sale 6 Jul 2026

Value US$100,000.00 | Price 50.84 | Shares 1,000

Planned sale 6 Jul 2026

Value US$100,000.00 | Price 49.98 | Shares 1,000

ORBIMED ADVISORS LLC

4 sales — total 39,014,046 USD

Sale 22 Jun 2026

Value US$2,104,920.00 | Price 45.00 | Shares 46,776

Sale 22 Jun 2026

Value US$35,715,149.12 | Price 45.38 | Shares 787,024

Sale 22 Jun 2026

Value US$66,465.00 | Price 45.00 | Shares 1,477

Sale 22 Jun 2026

Value US$1,127,511.48 | Price 45.38 | Shares 24,846

OrbiMed Genesis Master Fund, L.P.

Shareholder

4 sales — total 2,419,610 USD

Proposed sale 22 Jun 2026

Value US$67,882.92 | Price 45.96 | Shares 1,477

Proposed sale 22 Jun 2026

Value US$67,882.92 | Price 45.96 | Shares 1,477

Proposed sale 22 Jun 2026

Value US$1,141,922.16 | Price 45.96 | Shares 24,846

Proposed sale 22 Jun 2026

Value US$1,141,922.16 | Price 45.96 | Shares 24,846

OrbiMed Private Investments VII, LP

Shareholder

4 sales — total 76,642,896 USD

Proposed sale 22 Jun 2026

Value US$2,149,824.96 | Price 45.96 | Shares 46,776

Proposed sale 22 Jun 2026

Value US$2,149,824.96 | Price 45.96 | Shares 46,776

Proposed sale 22 Jun 2026

Value US$36,171,623.04 | Price 45.96 | Shares 787,024

Proposed sale 22 Jun 2026

Value US$36,171,623.04 | Price 45.96 | Shares 787,024

The Biotech Growth Trust PLC

Shareholder

4 sales — total 2,861,653 USD

Proposed sale 22 Jun 2026

Value US$80,292.12 | Price 45.96 | Shares 1,747

Proposed sale 22 Jun 2026

Value US$80,292.12 | Price 45.96 | Shares 1,747

Proposed sale 22 Jun 2026

Value US$1,350,534.60 | Price 45.96 | Shares 29,385

Proposed sale 22 Jun 2026

Value US$1,350,534.60 | Price 45.96 | Shares 29,385

Hohl Benjamin

CHIEF FINANCIAL OFFICER

7 sales — total 1,295,352 USD

Planned sale 17 Jun 2026

Value US$55,397.41 | Price 44.75 | Shares 1,238

Planned sale 17 Jun 2026

Value US$55,397.41 | Price 44.75 | Shares 1,238

Planned sale 17 Jun 2026

Value US$149,179.42 | Price 43.86 | Shares 3,401

Planned sale 17 Jun 2026

Value US$149,179.42 | Price 43.86 | Shares 3,401

Planned sale 17 Jun 2026

Value US$59,000.51 | Price 42.79 | Shares 1,379

Planned sale 17 Jun 2026

Value US$59,000.51 | Price 42.79 | Shares 1,379

Proposed sale 17 Jun 2026

Value US$768,197.70 | Price 42.55 | Shares 18,054

Collins Helen Louise

CHIEF MEDICAL OFFICER

6 sales — total 438,034 USD

Planned sale 17 Jun 2026

Value US$50,693.82 | Price 44.74 | Shares 1,133

Planned sale 17 Jun 2026

Value US$50,693.82 | Price 44.74 | Shares 1,133

Planned sale 17 Jun 2026

Value US$114,018.39 | Price 43.87 | Shares 2,599

Planned sale 17 Jun 2026

Value US$114,018.39 | Price 43.87 | Shares 2,599

Planned sale 17 Jun 2026

Value US$54,304.64 | Price 42.83 | Shares 1,268

Planned sale 17 Jun 2026

Value US$54,304.64 | Price 42.83 | Shares 1,268

ORBIMED ADVISORS LLC

2 sales — total 12,668,988 USD

Sale 15 Jun 2026

Value US$12,259,936.44 | Price 45.02 | Shares 272,322

Sale 15 Jun 2026

Value US$409,051.72 | Price 45.02 | Shares 9,086

The Biotech Growth Trust PLC

Shareholder

1 sale — total 433,893 USD

Proposed sale 15 Jun 2026

Value US$433,893.48 | Price 42.36 | Shares 10,243

OrbiMed Private Investments VII, LP

Shareholder

1 sale — total 11,535,560 USD

Proposed sale 15 Jun 2026

Value US$11,535,559.92 | Price 42.36 | Shares 272,322

OrbiMed Genesis Master Fund, L.P.

Shareholder

1 sale — total 384,883 USD

Proposed sale 15 Jun 2026

Value US$384,882.96 | Price 42.36 | Shares 9,086

Kunkel Lori Anne

5 sales — total 1,764,951 USD

Planned sale 5 Jun 2026

Value US$12,679.82 | Price 35.82 | Shares 354

Planned sale 5 Jun 2026

Value US$66,012.08 | Price 35.36 | Shares 1,867

Planned sale 5 Jun 2026

Value US$266,659.45 | Price 34.28 | Shares 7,779

Proposed sale 5 Jun 2026

Value US$709,800.00 | Price 35.49 | Shares 20,000

Proposed sale 5 Jun 2026

Value US$709,800.00 | Price 35.49 | Shares 20,000

Collins Helen Louise

CHIEF MEDICAL OFFICER

4 sales — total 819,071 USD

Planned sale 18 May 2026

Value US$9,188.76 | Price 41.21 | Shares 223

Planned sale 18 May 2026

Value US$52,401.98 | Price 40.25 | Shares 1,302

Planned sale 18 May 2026

Value US$137,380.65 | Price 39.53 | Shares 3,475

Proposed sale 18 May 2026

Value US$620,100.00 | Price 41.34 | Shares 15,000

Lyssikatos Joseph P

Officer

1 sale — total 1,060,000 USD

Proposed sale 30 Apr 2026

Value US$1,060,000.00 | Price 42.40 | Shares 25,000

Collins Helen Louise

CHIEF MEDICAL OFFICER

3 sales — total 238,352 USD

Planned sale 17 Apr 2026

Value US$117,303.48 | Price 48.06 | Shares 2,441

Planned sale 17 Apr 2026

Value US$114,635.44 | Price 47.39 | Shares 2,419

Planned sale 17 Apr 2026

Value US$6,413.50 | Price 45.81 | Shares 140

ANDREW PHILLIPS

Former Director

1 sale — total 1,003,610 USD

Proposed sale 31 Mar 2026

Value US$1,003,610.20 | Price 38.55 | Shares 26,035

Lyssikatos Joseph P

Officer

1 sale — total 914,750 USD

Proposed sale 31 Mar 2026

Value US$914,750.00 | Price 36.59 | Shares 25,000

Collins Helen Louise

CHIEF MEDICAL OFFICER

2 sales — total 2,805,774 USD

Planned sale 25 Mar 2026

Value US$1,404,024.00 | Price 35.10 | Shares 40,000

Proposed sale 25 Mar 2026

Value US$1,401,750.00 | Price 31.15 | Shares 45,000

Patel Anish

Officer

1 sale — total 3,081,000 USD

Proposed sale 24 Mar 2026

Value US$3,081,000.00 | Price 30.81 | Shares 100,000

Collins Helen Louise

CHIEF MEDICAL OFFICER

1 sale — total 138,800 USD

Planned sale 17 Mar 2026

Value US$138,800.00 | Price 27.76 | Shares 5,000

Collins Helen Louise

CHIEF MEDICAL OFFICER

1 sale — total 305,827 USD

Planned sale 10 Mar 2026

Value US$305,826.92 | Price 30.19 | Shares 10,129

Collins Helen Louise

CHIEF MEDICAL OFFICER

2 sales — total 2,221,611 USD

Planned sale 9 Mar 2026

Value US$896,811.06 | Price 30.02 | Shares 29,871

Proposed sale 9 Mar 2026

Value US$1,324,800.00 | Price 29.44 | Shares 45,000

Hohl Benjamin

CHIEF FINANCIAL OFFICER

2 sales — total 588,739 USD

Sale 6 Mar 2026

Value US$295,839.00 | Price 29.58 | Shares 10,000

Proposed sale 6 Mar 2026

Value US$292,900.00 | Price 29.29 | Shares 10,000

Lyssikatos Joseph P

Officer

1 sale — total 1,959,750 USD

Proposed sale 18 Feb 2026

Value US$1,959,750.00 | Price 26.13 | Shares 75,000

Heyman Richard A.

1 sale — total 32,196 USD

Planned sale 17 Feb 2026

Value US$32,196.36 | Price 26.18 | Shares 1,230

Collins Helen Louise

CHIEF MEDICAL OFFICER

1 sale — total 1,177,862 USD

Planned sale 17 Feb 2026

Value US$1,177,861.50 | Price 26.17 | Shares 45,000

Kintz Samuel

Officer

1 sale — total 2,004,000 USD

Proposed sale 17 Feb 2026

Value US$2,004,000.00 | Price 26.72 | Shares 75,000

Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other

Notification date	Transaction date	B/S Transaction type	Insider and/or position	Nb. shares Price Value	Number of shares	Price	Value
2026-07-21	2026-07-17	PlS Planned sale	0.5 Hohl Benjamin CHIEF FINANCIAL OFFICER Officer	29,127 +5.3% 234.18 US$621,546	29,127 +5.3%	234.18	US$621,546
2026-07-21	2026-07-17	PlS Planned sale	0.5 Hohl Benjamin CHIEF FINANCIAL OFFICER Officer	40,060 +45.4% 357.85 US$1,898,350	40,060 +45.4%	357.85	US$1,898,350
2026-07-21	2026-07-17	PlS Planned sale	0.5 Hohl Benjamin CHIEF FINANCIAL OFFICER Officer	64,389 -13.9% 99.90 US$3,283,050	64,389 -13.9%	99.90	US$3,283,050
2026-07-21	2026-07-17	PlS Planned sale	0.5 Hohl Benjamin CHIEF FINANCIAL OFFICER Officer	1,000 -0.7% 51.48 US$100,000	1,000 -0.7%	51.48	US$100,000
2026-07-21	2026-07-17	PlS Planned sale	0.5 Hohl Benjamin CHIEF FINANCIAL OFFICER Officer	1,000 -0.6% 49.97 US$100,000	1,000 -0.6%	49.97	US$100,000
2026-07-21	2026-07-17	PlS Planned sale	Collins Helen Louise CHIEF MEDICAL OFFICER Officer	1,000 -0.3% 53.92 US$100,000	1,000 -0.3%	53.92	US$100,000
2026-07-21	2026-07-17	PlS Planned sale	Collins Helen Louise CHIEF MEDICAL OFFICER Officer	1,000 -8.0% 53.42 US$100,000	1,000 -8.0%	53.42	US$100,000
2026-07-21	2026-07-17	PlS Planned sale	Collins Helen Louise CHIEF MEDICAL OFFICER Officer	1,000 -7.0% 52.39 US$100,000	1,000 -7.0%	52.39	US$100,000
2026-07-21	2026-07-17	PlS Planned sale	Collins Helen Louise CHIEF MEDICAL OFFICER Officer	1,000 -1.5% 51.55 US$100,000	1,000 -1.5%	51.55	US$100,000
2026-07-21	2026-07-17	PlS Planned sale	Collins Helen Louise CHIEF MEDICAL OFFICER Officer	1,000 -0.8% 50.05 US$100,000	1,000 -0.8%	50.05	US$100,000
2026-07-17	2026-07-17	PrS Proposed sale	Collins Helen Louise Officer Officer	1,000 50.86 US$100,000	1,000	50.86	US$100,000
2026-07-08	2026-07-06	PlS Planned sale	Kunkel Lori Anne Non-Executive Director	1,000 -12.3% 50.84 US$100,000	1,000 -12.3%	50.84	US$100,000
2026-07-08	2026-07-06	PlS Planned sale	Kunkel Lori Anne Non-Executive Director	1,000 -7.9% 49.98 US$100,000	1,000 -7.9%	49.98	US$100,000
2026-06-24	2026-06-22	S Sale	2.6 ORBIMED ADVISORS LLC Large shareholder	46,776 -0.7% 45.00 US$2,104,920	46,776 -0.7%	45.00	US$2,104,920
2026-06-24	2026-06-22	S Sale	2.6 ORBIMED ADVISORS LLC Large shareholder	787,024 -10.7% 45.38 US$35,715,149	787,024 -10.7%	45.38	US$35,715,149
2026-06-24	2026-06-22	S Sale	2.6 ORBIMED ADVISORS LLC Large shareholder	1,477 -0.7% 45.00 US$66,465	1,477 -0.7%	45.00	US$66,465
2026-06-24	2026-06-22	S Sale	2.6 ORBIMED ADVISORS LLC Large shareholder	24,846 -10.1% 45.38 US$1,127,511	24,846 -10.1%	45.38	US$1,127,511
2026-06-22	2026-06-22	PrS Proposed sale	2.6 OrbiMed Genesis Master Fund, L.P. Shareholder	1,477 45.96 US$67,883	1,477	45.96	US$67,883
2026-06-22	2026-06-22	PrS Proposed sale	2.6 OrbiMed Genesis Master Fund, L.P. Shareholder	1,477 45.96 US$67,883	1,477	45.96	US$67,883
2026-06-22	2026-06-22	PrS Proposed sale	2.6 OrbiMed Genesis Master Fund, L.P. Shareholder	24,846 45.96 US$1,141,922	24,846	45.96	US$1,141,922
2026-06-22	2026-06-22	PrS Proposed sale	2.6 OrbiMed Genesis Master Fund, L.P. Shareholder	24,846 45.96 US$1,141,922	24,846	45.96	US$1,141,922
2026-06-22	2026-06-22	PrS Proposed sale	2.6 OrbiMed Private Investments VII, LP Shareholder	46,776 45.96 US$2,149,825	46,776	45.96	US$2,149,825
2026-06-22	2026-06-22	PrS Proposed sale	2.6 OrbiMed Private Investments VII, LP Shareholder	46,776 45.96 US$2,149,825	46,776	45.96	US$2,149,825
2026-06-22	2026-06-22	PrS Proposed sale	2.6 OrbiMed Private Investments VII, LP Shareholder	787,024 45.96 US$36,171,623	787,024	45.96	US$36,171,623
2026-06-22	2026-06-22	PrS Proposed sale	2.6 OrbiMed Private Investments VII, LP Shareholder	787,024 45.96 US$36,171,623	787,024	45.96	US$36,171,623
2026-06-22	2026-06-22	PrS Proposed sale	The Biotech Growth Trust PLC Shareholder	1,747 45.96 US$80,292	1,747	45.96	US$80,292
2026-06-22	2026-06-22	PrS Proposed sale	The Biotech Growth Trust PLC Shareholder	1,747 45.96 US$80,292	1,747	45.96	US$80,292
2026-06-22	2026-06-22	PrS Proposed sale	The Biotech Growth Trust PLC Shareholder	29,385 45.96 US$1,350,535	29,385	45.96	US$1,350,535
2026-06-22	2026-06-22	PrS Proposed sale	The Biotech Growth Trust PLC Shareholder	29,385 45.96 US$1,350,535	29,385	45.96	US$1,350,535
2026-06-22	2026-06-17	PlS Planned sale	0.5 Hohl Benjamin CHIEF FINANCIAL OFFICER Officer	1,238 -2.4% 44.75 US$55,397	1,238 -2.4%	44.75	US$55,397
2026-06-22	2026-06-17	PlS Planned sale	0.5 Hohl Benjamin CHIEF FINANCIAL OFFICER Officer	1,238 -2.4% 44.75 US$55,397	1,238 -2.4%	44.75	US$55,397
2026-06-22	2026-06-17	PlS Planned sale	0.5 Hohl Benjamin CHIEF FINANCIAL OFFICER Officer	3,401 -6.1% 43.86 US$149,179	3,401 -6.1%	43.86	US$149,179
2026-06-22	2026-06-17	PlS Planned sale	0.5 Hohl Benjamin CHIEF FINANCIAL OFFICER Officer	3,401 -6.1% 43.86 US$149,179	3,401 -6.1%	43.86	US$149,179
2026-06-22	2026-06-17	PlS Planned sale	0.5 Hohl Benjamin CHIEF FINANCIAL OFFICER Officer	1,379 -2.4% 42.79 US$59,001	1,379 -2.4%	42.79	US$59,001
2026-06-22	2026-06-17	PlS Planned sale	0.5 Hohl Benjamin CHIEF FINANCIAL OFFICER Officer	1,379 -2.4% 42.79 US$59,001	1,379 -2.4%	42.79	US$59,001
2026-06-22	2026-06-17	PlS Planned sale	Collins Helen Louise CHIEF MEDICAL OFFICER Officer	1,133 -4.3% 44.74 US$50,694	1,133 -4.3%	44.74	US$50,694
2026-06-22	2026-06-17	PlS Planned sale	Collins Helen Louise CHIEF MEDICAL OFFICER Officer	1,133 -4.3% 44.74 US$50,694	1,133 -4.3%	44.74	US$50,694
2026-06-22	2026-06-17	PlS Planned sale	Collins Helen Louise CHIEF MEDICAL OFFICER Officer	2,599 -9.0% 43.87 US$114,018	2,599 -9.0%	43.87	US$114,018
2026-06-22	2026-06-17	PlS Planned sale	Collins Helen Louise CHIEF MEDICAL OFFICER Officer	2,599 -9.0% 43.87 US$114,018	2,599 -9.0%	43.87	US$114,018
2026-06-22	2026-06-17	PlS Planned sale	Collins Helen Louise CHIEF MEDICAL OFFICER Officer	1,268 -4.2% 42.83 US$54,305	1,268 -4.2%	42.83	US$54,305
2026-06-22	2026-06-17	PlS Planned sale	Collins Helen Louise CHIEF MEDICAL OFFICER Officer	1,268 -4.2% 42.83 US$54,305	1,268 -4.2%	42.83	US$54,305
2026-06-17	2026-06-17	PrS Proposed sale	0.5 Hohl Benjamin Officer Officer	18,054 42.55 US$768,198	18,054	42.55	US$768,198
2026-06-17	2026-06-15	S Sale	2.6 ORBIMED ADVISORS LLC Large shareholder	272,322 -3.6% 45.02 US$12,259,936	272,322 -3.6%	45.02	US$12,259,936
2026-06-17	2026-06-15	S Sale	2.6 ORBIMED ADVISORS LLC Large shareholder	9,086 -3.6% 45.02 US$409,052	9,086 -3.6%	45.02	US$409,052
2026-06-15	2026-06-15	PrS Proposed sale	The Biotech Growth Trust PLC Shareholder	10,243 42.36 US$433,893	10,243	42.36	US$433,893
2026-06-15	2026-06-15	PrS Proposed sale	2.6 OrbiMed Private Investments VII, LP Shareholder	272,322 42.36 US$11,535,560	272,322	42.36	US$11,535,560
2026-06-15	2026-06-15	PrS Proposed sale	2.6 OrbiMed Genesis Master Fund, L.P. Shareholder	9,086 42.36 US$384,883	9,086	42.36	US$384,883
2026-06-09	2026-06-05	PlS Planned sale	Kunkel Lori Anne Non-Executive Director	354 -0.7% 35.82 US$12,680	354 -0.7%	35.82	US$12,680
2026-06-09	2026-06-05	PlS Planned sale	Kunkel Lori Anne Non-Executive Director	1,867 -3.5% 35.36 US$66,012	1,867 -3.5%	35.36	US$66,012
2026-06-09	2026-06-05	PlS Planned sale	Kunkel Lori Anne Non-Executive Director	7,779 -12.6% 34.28 US$266,659	7,779 -12.6%	34.28	US$266,659
2026-06-05	2026-06-05	PrS Proposed sale	Kunkel Lori Anne Board Member	20,000 35.49 US$709,800	20,000	35.49	US$709,800
2026-06-05	2026-06-05	PrS Proposed sale	Kunkel Lori Anne Board Member	20,000 35.49 US$709,800	20,000	35.49	US$709,800
2026-05-20	2026-05-18	PlS Planned sale	Collins Helen Louise CHIEF MEDICAL OFFICER Officer	223 -0.9% 41.21 US$9,189	223 -0.9%	41.21	US$9,189
2026-05-20	2026-05-18	PlS Planned sale	Collins Helen Louise CHIEF MEDICAL OFFICER Officer	1,302 -4.9% 40.25 US$52,402	1,302 -4.9%	40.25	US$52,402
2026-05-20	2026-05-18	PlS Planned sale	Collins Helen Louise CHIEF MEDICAL OFFICER Officer	3,475 -11.6% 39.53 US$137,381	3,475 -11.6%	39.53	US$137,381
2026-05-18	2026-05-18	PrS Proposed sale	Collins Helen Louise Officer Officer	15,000 41.34 US$620,100	15,000	41.34	US$620,100
2026-04-30	2026-04-30	PrS Proposed sale	Lyssikatos Joseph P Officer Officer	25,000 42.40 US$1,060,000	25,000	42.40	US$1,060,000
2026-04-21	2026-04-17	PlS Planned sale	Collins Helen Louise CHIEF MEDICAL OFFICER Officer	2,441 -8.9% 48.06 US$117,303	2,441 -8.9%	48.06	US$117,303
2026-04-21	2026-04-17	PlS Planned sale	Collins Helen Louise CHIEF MEDICAL OFFICER Officer	2,419 -8.1% 47.39 US$114,635	2,419 -8.1%	47.39	US$114,635
2026-04-21	2026-04-17	PlS Planned sale	Collins Helen Louise CHIEF MEDICAL OFFICER Officer	140 -0.5% 45.81 US$6,413	140 -0.5%	45.81	US$6,413
2026-03-31	2026-03-31	PrS Proposed sale	ANDREW PHILLIPS Former Director Non-Executive Director	26,035 38.55 US$1,003,610	26,035	38.55	US$1,003,610
2026-03-31	2026-03-31	PrS Proposed sale	Lyssikatos Joseph P Officer Officer	25,000 36.59 US$914,750	25,000	36.59	US$914,750
2026-03-27	2026-03-25	PlS Planned sale	Collins Helen Louise CHIEF MEDICAL OFFICER Officer	40,000 -61.5% 35.10 US$1,404,024	40,000 -61.5%	35.10	US$1,404,024
2026-03-25	2026-03-25	PrS Proposed sale	Collins Helen Louise Officer Officer	45,000 31.15 US$1,401,750	45,000	31.15	US$1,401,750
2026-03-24	2026-03-24	PrS Proposed sale	Patel Anish Officer Officer	100,000 30.81 US$3,081,000	100,000	30.81	US$3,081,000
2026-03-19	2026-03-17	PlS Planned sale	Collins Helen Louise CHIEF MEDICAL OFFICER Officer	5,000 -16.7% 27.76 US$138,800	5,000 -16.7%	27.76	US$138,800
2026-03-11	2026-03-10	PlS Planned sale	Collins Helen Louise CHIEF MEDICAL OFFICER Officer	10,129 -28.8% 30.19 US$305,827	10,129 -28.8%	30.19	US$305,827
2026-03-11	2026-03-09	PlS Planned sale	Collins Helen Louise CHIEF MEDICAL OFFICER Officer	29,871 -54.4% 30.02 US$896,811	29,871 -54.4%	30.02	US$896,811
2026-03-09	2026-03-09	PrS Proposed sale	Collins Helen Louise Officer Officer	45,000 29.44 US$1,324,800	45,000	29.44	US$1,324,800
2026-03-10	2026-03-06	S Sale	0.5 Hohl Benjamin CHIEF FINANCIAL OFFICER Officer	10,000 -16.4% 29.58 US$295,839	10,000 -16.4%	29.58	US$295,839
2026-03-06	2026-03-06	PrS Proposed sale	0.5 Hohl Benjamin Officer Officer	10,000 29.29 US$292,900	10,000	29.29	US$292,900
2026-02-18	2026-02-18	PrS Proposed sale	Lyssikatos Joseph P Officer Officer	75,000 26.13 US$1,959,750	75,000	26.13	US$1,959,750
2026-02-19	2026-02-17	PlS Planned sale	Heyman Richard A. Non-Executive Director	1,230 -5.2% 26.18 US$32,196	1,230 -5.2%	26.18	US$32,196
2026-02-19	2026-02-17	PlS Planned sale	Collins Helen Louise CHIEF MEDICAL OFFICER Officer	45,000 -64.3% 26.17 US$1,177,862	45,000 -64.3%	26.17	US$1,177,862
2026-02-17	2026-02-17	PrS Proposed sale	Kintz Samuel Officer Officer	75,000 26.72 US$2,004,000	75,000	26.72	US$2,004,000

Explore more

More insider trading research around Enliven Therapeutics Inc

More insider trades in United States

Similar Healthcare companies with insider activity

More Pharmaceuticals & Medical Research companies with insider activity

More Biotechnology & Medical Research companies with insider activity

Insider trading in North America

Enliven Therapeutics Inc (ELVN)

Track

Featured in screeners

Upgrade for signal details

Transactions

Insider

Sort by

Trades

Explore more